CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement
PR93199
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
SUZHOU, China, Nov. 21, 2021 /PRNewswire=KYODO JBN/ --
- CStone granted the exclusive rights to Hengrui for research, development,
registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in
the Greater China region
- CStone will retain the rights to develop and commercialize anti-CTLA-4 mAb
CS1002 outside of Greater China
- CStone and Hengrui will partner respective R&D and commercial expertise to
accelerate the development and commercialization of anti-CTLA-4 mAb CS1002, a
backbone immuno-oncology asset, to fully unleash its commercial value
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical
company focused on the research, development, and commercialization of
innovative immuno-oncology therapies and precision medicines, and Jiangsu
Hengrui Pharmaceuticals ("Hengrui", SHSE: 600276) today announced a strategic
partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the
Greater China region. This strategic partnership marks another milestone in
CStone's mission to introduce innovative oncology therapies in China after the
commercial launch of two first-in-class drugs this year.
Under the terms of the agreement, CStone will be eligible for an upfront
payment and potential milestone payments up to $200 Mn in addition to
double-digit royalties. Hengrui will obtain the exclusive rights for research,
development, registration, manufacturing, and commercialization of anti-CTLA-4
mAb CS1002 in Greater China. CStone will retain the rights to develop and
commercialize of CS1002 outside of Greater China.
Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) is one of the few
clinically validated targets for IO combination therapies. There is only one
anti-CTLA-4 monoclonal antibody approved globally, and it is also approved in
China. According to EvaluatePharma, the annual global revenue of the product in
2020 was approximately $1.69 billion. CS1002 is an investigational anti-CTLA-4
monoclonal antibody being developed by CStone currently in clinical
development. Results from the ongoing Ph1a/1b study showed that differentiated
dosing schedules of CS1002 in combination with CS1003 (anti-PD-1) were
well-tolerated and demonstrated very encouraging efficacy in
anti-PD-(L)1-refractory melanoma, anti-PD-(L)1-refractory hepatocellular
carcinoma, and anti-PD-(L)1-naïve, pretreated microsatellite instability
high/deficient mismatch repair (MSI-H/dMMR) tumors.
Dr. Frank Jiang, Chairman and CEO of CStone, said, "We are happy to reach the
partnership with Hengrui. As a leading global China pharmaceutical company with
an extensive oncology pipeline and strong integrated capabilities in
commercialization, we are very confident that Hengrui will bring the full
potentialities of CS1002 into the Greater China market. Through this
collaboration, we believe we will join forces to bring forward more
high-quality innovative oncology therapies to patients."
Dr. Lianshan Zhang, Member of the Board, Senior Vice President and President of
global R&D of Hengrui, said, "We are happy to enter into this collaboration
with CStone on the backbone immune-oncology asset of CS1002. With its
combination therapy potential, CS1002 will further synergize our pipeline,
enrich the oncology portfolio and strengthen our competitiveness. As a leading
Chinese biopharmaceutical company, CStone has demonstrated its outstanding
research and development capabilities with impressive early-stage clinical data
and differentiated dosing schedules of CS1002. We have full confidence in the
future development of it to provide more innovative drugs for Chinese patients."
About CS1002 (anti-CTLA-4 antibody)
CS1002 is an investigational anti-CTLA-4 monoclonal antibody being developed by
CStone. CS1002 is differentiated from prior CTLA-4 targeting drug in its dosing
schedules that have been tested in early development and the encouraging
efficacy and safety in three indications providing proof-of-concept for CS1002
as a potential backbone for IO combinations. Cytotoxic T lymphocyte associated
antigen 4 (CTLA-4), also known as CD152, is a transmembrane protein encoded by
the CTLA-4 gene that can down-regulate the activity of T cells when binding
with its ligand, B7, a pathway also used by tumor cells to avoid T lymphocyte
attack. Consequently, blockade of the CTLA-4 pathway can stimulate T cell
activation and proliferation to induce or enhance anti-tumor immune responses.
CTLA-4 provides a new immuno-therapeutic approach to a number of human cancers.
About CStone
CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on
researching, developing, and commercializing innovative immuno-oncology and
precision medicines to address the unmet medical needs of cancer patients in
China and worldwide. Established in 2015, CStone has assembled a world-class
management team with extensive experience in innovative drug development,
clinical research, and commercialization. The company has built an
oncology-focused pipeline of 15 drug candidates with a strategic emphasis on
immuno-oncology combination therapies. Currently, CStone has received three
drug approvals in Greater China, including two in Mainland China and one in
Taiwan. CStone's vision is to become globally recognized as a world-renowned
biopharmaceutical company by bringing innovative oncology therapies to cancer
patients worldwide.
For more information about CStone, please visit: www.cstonepharma.com.
About Hengrui
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading global pharmaceutical
company based in China with a focus on research, development, manufacturing and
commercialization of innovative and high–quality healthcare products.
Innovation is the core development strategy. Hengrui Pharma has 8 innovative
products marketed, more than 50 innovative candidates in the R&D stage, more
than 20 innovative products under clinical development around the world.
Hengrui Pharma ranked 21st among the top 1,000 global pharma companies
announced by the Torreya in 2020. Hengrui Pharma has been on the Pharma Exec's
annual listing of the top global pharmaceutical companies for the third
consecutive year, rising from 47th in 2019 to 38th in 2021.
Forward-looking statement
The forward-looking statements made in this article only relate to events or
information as of the date when the statements are made in this article. Except
as required by law, we undertake no obligation to update or publicly revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, after the date on which the statements are made or to
reflect the occurrence of unanticipated events. You should read this article
completely and with the understanding that our actual future results or
performance may be materially different from what we expect. All statements in
this article are made on the date of publication of this article and may change
due to future developments.
SOURCE: CStone Pharmaceuticals
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。